PSMA PET for the Staging and Management of Hepatocellular Carcinoma (NCT07019844)
Addition of F18-Piflufolastat PET/CT to Cross-Sectional Imaging for the Staging and Management of Hepatocellular Carcinoma
🩺 Plain-English Summary (8th-Grade Level)
This prospective, single-center study evaluates the clinical utility of F18-Piflufolastat (PSMA) PET/CT when added to conventional cross-sectional imaging for patients with suspected or confirmed hepatocellular carcinoma (HCC). The study aims to determine whether PSMA PET/CT improves diagnostic accuracy for indeterminate liver lesions (LI-RADS 3 and 4), enhances staging precision in treatment-naïve patients, and provides more accurate assessment of treatment response in patients undergoing locoregional therapy (LRT). The goal is to assess how PSMA PET/CT may impact clinical decision-making, staging, and management of HCC across multiple stages of disease.
Who can join: Review the eligibility criteria below.
Location: VA Greater Los Angeles Healthcare System, West Los Angeles, CA — West Los Angeles, California
Age range: 18 Years
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (2 Sites)
- VA Greater Los Angeles Healthcare System, West Los Angeles, CA — West Los Angeles, California
- Miami VA Healthcare System, Miami, FL — Miami, Florida
📞 Contact the Study Coordinator
Phone: (305) 575-7000
Email: binu.john@va.gov
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Hepatocellular Carcinoma (HCC)
- Streamlined Resin Y90 Radiation Segmentectomy for Small HCC — Chapel Hill, North Carolina
- A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE — Aurora, Colorado
- Utilize Imaging to Assess Changes in Hepatocellular Carcinoma Perfusion as Potentiated by Intra-Arterial Nitroglycerin — San Francisco, California
- Radiation Therapy Followed by Durvalumab (MEDI4736) and Tremelimumab And Surgery Versus Radiation Therapy Followed by Surgery for Resectable Hepatocellular Carcinoma. — Hamilton, Ontario
- Using Radiotherapy and Immunotherapy to Treat Advanced Liver Cancer Before Transplant — London, Ontario
- Liquid Biopsy for Hepatocellular Carcinoma Molecular Characterization After Y90 — Palo Alto, California
Explore by condition: All Hepatocellular Carcinoma (HCC) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.